source
- Novo Nordisk acquires three early-stage obesity programs from KallyopeNovo Nordisk announced the purchase of three early-stage obesity drug programs from New York‑based biotech Kallyope, expanding its metabolic pipeline. The acquired assets are not GLP‑1 incretins.…
- Electra Therapeutics raises $350M in biotech IPO, fueling rare disease drug developmentElectra Therapeutics completed a $350 million initial public offering, becoming the 21st biotechnology company to go public in 2026. The strong demand for its shares highlights continued investor a…